secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-01-15T23:59:59+00:00
Accession:  0001104659-25-003755
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports ~$420M cash; DMD pipeline advancing with multiple 2025 trial starts
--------------------------------------------------------------------------------

- Preliminary cash resources ~$420M as of Dec 31, 2024, extending runway into Q2 2027.
- Phase 1 ENTR-601-44 data: no treatment-related AEs; dose-dependent PK/PD and statistically significant exon skipping at 6 mg/kg.
- Plans to initiate Phase 1/2 MAD studies for ENTR-601-44, -45, -50, and -51 in 2025; Vertex advancing VX-670 MAD portion in DM1.
- Preclinical data show dose-dependent dystrophin restoration and functional correction in DMD mouse models across franchise.
- Cash and clinical updates based on preliminary unaudited estimates; year-end audit ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/0001104659-25-003755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465925003755/tm253290d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer